CFO Mark Saad presents at Biocentury's Future Leaders in the Biotech Industryon Friday, April 5

1. C Y TherapyI
Personalized Cell TOR
BioCentury Future Leaders Conference
April 5, 2013
NASDAQ: CYTX 1

2. Safe Harbor Statement
This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All
statements, other than statements of historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate will or may occur in the future are forward-
looking statements. Such statements are based upon certain assumptions and assessments made by
our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.
The forward-looking statements included in this presentation involve known and unknown risks that
relate to Cytori’s future events or future financial performance and the actual results could differ
materially from those discussed in this presentation. Risks and uncertainties that may cause Cytori's
actual results to differ materially from those discussed in the presentation can be found in the "Risk
Factors" section of Cytori’s Form 10-K, Forms 10-Q and other filings with the United States Securities
and Exchange Commission. We would advise reading our most recent annual report on Form 10-K
and quarterly report on Form 10-Q filed with the United States Securities and Exchange Commission
for a more detailed description of these risks.
The forward-looking statements contained in this presentation represent Cytori’s estimates and
assumptions only as of the date of this presentation and Cytori undertakes no duty or obligation to
update or revise publicly any forward-looking statements contained in this presentation as a result of
new information, future events or changes in Cytori’s expectations.
2

3. Cytori Cell Therapy
① Game changing technology platform
② Arriving at points of leverage
• US Cardiac Data
• Barda Contract
• International Revenues
③ Expansive IP portfolio protects technology long-term
3

4. Cytori Cell Therapy
Proprietary formulation of a patient’s own adipose-
derived stem and regenerative cells
• Autologous
• Virtual ‘off the shelf’
• Mixed population
• Multiple mechanisms
• Patented process
4

5. Cytori Cell Therapy: Multiple Cell Types
Vascular
Smooth 45
Muscle Cells
Endothelial 9% Tissue
cells 7%
Macrophages 30
23%
White Blood
CD34+/CD31 15
- 37% Cells
22%
0
Total Nucleated Cells in Adipose
Stem
Cells 2%
Heterogeneous Cell Therapy uniquely leverages multiple mechanisms
5

6. Cytori Cell Therapy: System + Single-Use Cartridge
Processing System:
Low six figure ASP
Per-procedure consumable:
$2,000-$12,000
Dependent on indications
and formulation
60-80% Margin
6

7. Cytori Cell Therapy: Business Overview
Cardiac • US heart failure trial
BARDA Commercial
• Up to $106 in development funding • Japan research market
• US Government large end-customer • EU vascular approval
• Cytori to sell into all other burn markets • EU tissue ischemia approvals
• Cell & tissue banking

8. PRECISE Trial
20.0
19.0
P<0.05 P<0.02
18.0
VO2Max
17.2 17.1
ADRC’s
16.6 Increased
16.0 Mortality
15.5 Standard of Care
15.3
14.0 Transplant List
Baseline 6 Mos 18 Mos
Change in Peak Oxygen Consumption (VO2Max) from Baseline to 6 & 18 months 8
N=27; 21 active, 6 control

9. PRECISE Trial: Max VO2 a Predictor of 1 Yr. Survival
Reflects the degree of impairment in:
• Ventricular function (pumping
capacity)
• Vascular function (O2 delivery),
• Skeletal muscle metabolic capacity
(O2 utilization).
Pts with Max VO2 ≤ 14 ml/kg/min had
a 1 year survival rate of only 47%.
Mancini et al, Circulation 1991
Figure: Survival curves for all patients
subdivided by Max VO2 & EF
(p<0.05; VO2 ≤ 10 vs. > 14 ml/kg/min)

10. U.S. Refractory Heart Failure Trial
Status:
All centers actively screening
• Minneapolis Heart Institute (Timothy Henry MD)
• Texas Heart Institute (Emerson Perin MD, PhD, James, Willerson, MD)
• University of Florida (Carl Pepine MD)
• University of South Florida (Leslie W. Miller MD)
• Scripps Green Hospital (Richard Schatz MD)
• Cardiology P.C. (Farrell Mendlesohn MD)
On-track to complete mid-Summer 2013
6-month data first half 2014
Pivotal Trial Design
• Detailed protocol and trial size to be determined by ATHENA outcomes
• Likely endpoints to include a functional and composite clinical outcome
10

11. BARDA: Up to $106 MM for Thermal Burn Development
U.S. Govt. contract: Thermal burns combined with radiation injury
• National preparedness to counter radiological bomb
• Funds complete development: preclinical to FDA submission
• New soft tissue pipeline application in U.S.
• Procurement potential above and beyond contract
Options 1 & 2
• $4.7 MM in funding • Up to $45 MM
• Preclinical model • Pivotal trial
• Up to $55 MM
• Next-Gen Celution® • FDA submission
• Development
development
including clinical
• Up to 2 years
• Govt. has
Proof-of- procurement ability Option 3
Concept
11

12. BARDA: Supporting Desktop System Development
Celution® System product and technological evolution
1. Cytori developed interim Celution 800 System (Cytori)
2. Olympus designed Celution One System (OC-JV)
3. Cytori designed Next Gen System (BARDA)
1. 2. 3.
Smaller. Faster. Cheaper. Higher Yields.

13. Translational Medicine: Near-Term Revenue Driver
Investigator-initiated trials resulting in:
• Meaningful sales to offset burn Vascular CE
Mark
Radiation
• Expansion of physician and injury
hospital network
• Strategic benefit of development Incontinence
of new applications/pipeline
Pivotal trials, grants (BARDA),
partnerships, regulatory
approvals, reimbursement

14. Financials
Current Select Data
PF cash & AR (YE 2012) $32 MM
Senior Term Loan (GE) $22 MM maturing in 2015
Shares outstanding 67 MM
Warrants 10 MM @ $3.25 avg. exercise price
2013 Guidance
Revenue $15 MM ($12 m product, $3 m contract)
SG&A Flat for year
R&D Slight increase, more than offset by BARDA revenue

15. 2013 Milestones
Present / Publish PRECISE long-term data (18 months)
Complete patient enrollment in ATHENA by mid-summer 2013
Advance BARDA toward Phase II
Achieve $15 million revenue target for 2013 (incl $2.5 - 3m Barda)
Expand Celution approvals ( ie Canada, Australia)

16. Personalized CellQ&A
Therapy